{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T16:04:13Z","timestamp":1773936253520,"version":"3.50.1"},"reference-count":76,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T00:00:00Z","timestamp":1768780800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"vor","delay-in-days":21,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"CRANIA support funds"},{"name":"Wolfond and Krembil Chair in PD Research"},{"name":"RR Tasker Chair in Functional Neurosurgery"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-34884-6","type":"journal-article","created":{"date-parts":[[2026,1,19]],"date-time":"2026-01-19T15:45:40Z","timestamp":1768837540000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of motor and non-motor features associated with bilateral nigral degeneration due to A53T alpha-synuclein in female rats"],"prefix":"10.1038","volume":"16","author":[{"given":"Laura","family":"Kondrataviciute","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Minesh","family":"Kapadia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hien","family":"Chau","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cherisse","family":"Tan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Polly","family":"Ou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritisha","family":"Mukherjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabika","family":"Jafri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jimmy","family":"George","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivan","family":"Skelin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taufik","family":"Valiante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luka","family":"Milosevic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lorraine V.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suneil K.","family":"Kalia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,19]]},"reference":[{"key":"34884_CR1","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1002\/ana.23746","volume":"73","author":"LV Kalia","year":"2013","unstructured":"Kalia, L. V., Kalia, S. K., McLean, P. J., Lozano, A. M. & Lang, A. E. \u03b1-Synuclein oligomers and clinical implications for Parkinson disease. Ann. Neurol. 73, 155\u2013169 (2013).","journal-title":"Ann. Neurol."},{"key":"34884_CR2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s13024-019-0329-1","volume":"14","author":"RM Meade","year":"2019","unstructured":"Meade, R. M., Fairlie, D. P. & Mason, J. M. Alpha-synuclein structure and Parkinson\u2019s disease \u2013 lessons and emerging principles. Mol. Neurodegener. 14, 29 (2019).","journal-title":"Mol. Neurodegener."},{"key":"34884_CR3","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1038\/s41419-023-05672-9","volume":"14","author":"P Calabresi","year":"2023","unstructured":"Calabresi, P. et al. Alpha-synuclein in Parkinson\u2019s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction. Cell Death Dis. 14, 176 (2023).","journal-title":"Cell Death Dis."},{"key":"34884_CR4","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1038\/nrn.2017.75","volume":"18","author":"JB Koprich","year":"2017","unstructured":"Koprich, J. B., Kalia, L. V. & Brotchie, J. M. Animal models of \u03b1-synucleinopathy for Parkinson disease drug development. Nat. Rev. Neurosci. 18, 515\u2013529 (2017).","journal-title":"Nat. Rev. Neurosci."},{"key":"34884_CR5","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1007\/s00702-021-02456-3","volume":"129","author":"G Laux","year":"2022","unstructured":"Laux, G. Parkinson and depression: Review and outlook. J. Neural. Transm. 129, 601\u2013608 (2022).","journal-title":"J. Neural. Transm."},{"key":"34884_CR6","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1002\/mds.26643","volume":"31","author":"MPG Broen","year":"2016","unstructured":"Broen, M. P. G., Narayen, N. E., Kuijf, M. L., Dissanayaka, N. N. W. & Leentjens, A. F. G. Prevalence of anxiety in Parkinson\u2019s disease: A systematic review and meta-analysis. Mov. Disord. 31, 1125\u20131133 (2016).","journal-title":"Mov. Disord."},{"key":"34884_CR7","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1016\/S1474-4422(10)70212-X","volume":"9","author":"AA Kehagia","year":"2010","unstructured":"Kehagia, A. A., Barker, R. A. & Robbins, T. W. Neuropsychological and clinical heterogeneity of cognitive impairment and dementia in patients with Parkinson\u2019s disease. Lancet Neurol. 9, 1200\u20131213 (2010).","journal-title":"Lancet Neurol."},{"key":"34884_CR8","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1038\/nrneurol.2012.80","volume":"8","author":"RL Doty","year":"2012","unstructured":"Doty, R. L. Olfactory dysfunction in Parkinson disease. Nat. Rev. Neurol. 8, 329\u2013339 (2012).","journal-title":"Nat. Rev. Neurol."},{"key":"34884_CR9","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1016\/j.neuron.2019.03.004","volume":"101","author":"MM McGregor","year":"2019","unstructured":"McGregor, M. M. & Nelson, A. B. Circuit mechanisms of Parkinson\u2019s disease. Neuron 101, 1042\u20131056 (2019).","journal-title":"Neuron"},{"key":"34884_CR10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1016\/S1474-4422(06)70373-8","volume":"5","author":"KR Chaudhuri","year":"2006","unstructured":"Chaudhuri, K. R., Healy, D. G. & Schapira, A. H. Non-motor symptoms of Parkinson\u2019s disease: Diagnosis and management. Lancet Neurol. 5, 235\u2013245 (2006).","journal-title":"Lancet Neurol."},{"key":"34884_CR11","doi-asserted-by":"publisher","first-page":"612","DOI":"10.3390\/biom11040612","volume":"11","author":"FC Church","year":"2021","unstructured":"Church, F. C. Treatment options for motor and non-motor symptoms of Parkinson\u2019s disease. Biomolecules 11, 612 (2021).","journal-title":"Biomolecules"},{"key":"34884_CR12","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1038\/s41583-021-00542-9","volume":"23","author":"J Blesa","year":"2022","unstructured":"Blesa, J., Foffani, G., Dehay, B., Bezard, E. & Obeso, J. A. Motor and non-motor circuit disturbances in early Parkinson disease: Which happens first?. Nat. Rev. Neurosci. 23, 115\u2013128 (2022).","journal-title":"Nat. Rev. Neurosci."},{"key":"34884_CR13","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1136\/jnnp.2010.213652","volume":"82","author":"RG Brown","year":"2011","unstructured":"Brown, R. G. et al. Depression and anxiety related subtypes in Parkinson\u2019s disease. J. Neurol. Neurosurg. Psychiatry 82, 803\u2013809 (2011).","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"34884_CR14","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41531-021-00259-7","volume":"7","author":"F Chen","year":"2021","unstructured":"Chen, F. et al. \u03b1-Synuclein aggregation in the olfactory bulb induces olfactory deficits by perturbing granule cells and granular\u2013mitral synaptic transmission. NPJ Parkinsons Dis. 7, 114 (2021).","journal-title":"NPJ Parkinsons Dis."},{"key":"34884_CR15","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1007\/s12264-017-0170-x","volume":"33","author":"ME Fullard","year":"2017","unstructured":"Fullard, M. E., Morley, J. F. & Duda, J. E. Olfactory dysfunction as an early biomarker in Parkinson\u2019s disease. Neurosci. Bull. 33, 515\u2013525 (2017).","journal-title":"Neurosci. Bull."},{"key":"34884_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1159\/000068483","volume":"15","author":"C Janvin","year":"2003","unstructured":"Janvin, C., Aarsland, D., Larsen, J. P. & Hugdahl, K. Neuropsychological profile of patients with Parkinson\u2019s disease without dementia. Dement. Geriatr. Cogn. Disord. 15, 126\u2013131 (2003).","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"34884_CR17","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1002\/mds.10280","volume":"17","author":"G Levy","year":"2002","unstructured":"Levy, G. et al. Memory and executive function impairment predict dementia in Parkinson\u2019s disease. Mov. Disord. 17, 1221\u20131226 (2002).","journal-title":"Mov. Disord."},{"key":"34884_CR18","doi-asserted-by":"publisher","first-page":"10775","DOI":"10.1038\/s41467-024-54945-0","volume":"15","author":"HF Khan","year":"2024","unstructured":"Khan, H. F. et al. Site-specific seeding of Lewy pathology induces distinct pre-motor cellular and dendritic vulnerabilities in the cortex. Nat. Commun. 15, 10775 (2024).","journal-title":"Nat. Commun."},{"key":"34884_CR19","doi-asserted-by":"publisher","first-page":"1265","DOI":"10.3390\/cells13151265","volume":"13","author":"GM Mazzotta","year":"2024","unstructured":"Mazzotta, G. M. & Conte, C. Alpha synuclein toxicity and non-motor Parkinson\u2019s. Cells 13, 1265 (2024).","journal-title":"Cells"},{"key":"34884_CR20","doi-asserted-by":"crossref","unstructured":"Konnova, E. A. & Swanberg, M. Animal models of Parkinson\u2019s disease. in Parkinson\u2019s Disease: Pathogenesis and Clinical Aspects 83\u2013106 (Codon Publications, 2018).","DOI":"10.15586\/codonpublications.parkinsonsdisease.2018.ch5"},{"key":"34884_CR21","doi-asserted-by":"crossref","unstructured":"Blesa, J. & Przedborski, S. Parkinson\u2019s disease: Animal models and dopaminergic cell vulnerability. Front. Neuroanat. 8, 155 (2014).","DOI":"10.3389\/fnana.2014.00155"},{"key":"34884_CR22","doi-asserted-by":"crossref","unstructured":"Cenci, M. A. & Bj\u00f6rklund, A. Animal models for preclinical Parkinson\u2019s research: An update and critical appraisal. 252, 27\u201359 (2020).","DOI":"10.1016\/bs.pbr.2020.02.003"},{"key":"34884_CR23","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s00441-004-0938-y","volume":"318","author":"A Schober","year":"2004","unstructured":"Schober, A. Classic toxin-induced animal models of Parkinson\u2019s disease: 6-OHDA and MPTP. Cell Tissue Res 318, 215\u2013224 (2004).","journal-title":"Cell Tissue Res"},{"key":"34884_CR24","doi-asserted-by":"publisher","first-page":"249","DOI":"10.3233\/JPD-012138","volume":"2","author":"NM Kanaan","year":"2012","unstructured":"Kanaan, N. M. & Manfredsson, F. P. Loss of functional alpha-synuclein: A toxic event in Parkinson\u2019s disease?. J. Parkinsons Dis. 2, 249\u2013267 (2012).","journal-title":"J. Parkinsons Dis."},{"key":"34884_CR25","doi-asserted-by":"publisher","first-page":"242","DOI":"10.1016\/j.jchemneu.2010.12.001","volume":"42","author":"F Cheng","year":"2011","unstructured":"Cheng, F., Vivacqua, G. & Yu, S. The role of alpha-synuclein in neurotransmission and synaptic plasticity. J. Chem. Neuroanat. 42, 242\u2013248 (2011).","journal-title":"J. Chem. Neuroanat."},{"key":"34884_CR26","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.neuron.2010.04.034","volume":"66","author":"TM Dawson","year":"2010","unstructured":"Dawson, T. M., Ko, H. S. & Dawson, V. L. Genetic animal models of Parkinson\u2019s disease. Neuron 66, 646\u2013661 (2010).","journal-title":"Neuron"},{"key":"34884_CR27","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.nbd.2004.07.001","volume":"17","author":"P-O Fernagut","year":"2004","unstructured":"Fernagut, P.-O. & Chesselet, M.-F. Alpha-synuclein and transgenic mouse models. Neurobiol. Dis. 17, 123\u2013130 (2004).","journal-title":"Neurobiol. Dis."},{"key":"34884_CR28","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s40478-017-0416-x","volume":"5","author":"CW Ip","year":"2017","unstructured":"Ip, C. W. et al. AAV1\/2-induced overexpression of A53T-\u03b1-synuclein in the substantia nigra results in degeneration of the nigrostriatal system with Lewy-like pathology and motor impairment: a new mouse model for Parkinson\u2019s disease. Acta Neuropathol. Commun. 5, 11 (2017).","journal-title":"Acta Neuropathol. Commun."},{"key":"34884_CR29","doi-asserted-by":"publisher","first-page":"3365","DOI":"10.1523\/JNEUROSCI.5427-08.2009","volume":"29","author":"CY Chung","year":"2009","unstructured":"Chung, C. Y., Koprich, J. B., Siddiqi, H. & Isacson, O. Dynamic changes in presynaptic and axonal transport proteins combined with striatal neuroinflammation precede dopaminergic neuronal loss in a rat model of AAV \u03b1-synucleinopathy. J. Neurosci. 29, 3365\u20133373 (2009).","journal-title":"J. Neurosci."},{"key":"34884_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0017698","volume":"6","author":"JB Koprich","year":"2011","unstructured":"Koprich, J. B. et al. Progressive neurodegeneration or endogenous compensation in an animal model of Parkinson\u2019s disease produced by decreasing doses of alpha-synuclein. PLoS ONE 6, e17698 (2011).","journal-title":"PLoS ONE"},{"key":"34884_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbr.2022.113968","volume":"432","author":"T Musacchio","year":"2022","unstructured":"Musacchio, T. et al. Temporal, spatial and molecular pattern of dopaminergic neurodegeneration in the AAV-A53T \u03b1-synuclein rat model of Parkinson\u2019s disease. Behav. Brain Res. 432, 113968 (2022).","journal-title":"Behav. Brain Res."},{"key":"34884_CR32","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1186\/1750-1326-5-43","volume":"5","author":"JB Koprich","year":"2010","unstructured":"Koprich, J. B., Johnston, T. H., Reyes, M. G., Sun, X. & Brotchie, J. M. Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1\/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson\u2019s disease. Mol. Neurodegener. 5, 43 (2010).","journal-title":"Mol. Neurodegener."},{"key":"34884_CR33","doi-asserted-by":"crossref","unstructured":"Musacchio, T., Koprich, J. B. & Ip, C. W. Modeling with the A53T \u03b1-synuclein model of Parkinson\u2019s disease. in Genetics, Neurology, Behavior, and Diet in Parkinson\u2019s Disease 677\u2013687 (Elsevier, 2020).","DOI":"10.1016\/B978-0-12-815950-7.00043-6"},{"key":"34884_CR34","doi-asserted-by":"crossref","unstructured":"Campos, F. L. et al. Rodent models of Parkinson\u2019s disease: Beyond the motor symptomatology. Front. Behav. Neurosci. 7, 175 (2013).","DOI":"10.3389\/fnbeh.2013.00175"},{"key":"34884_CR35","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.expneurol.2015.09.002","volume":"273","author":"D Caudal","year":"2015","unstructured":"Caudal, D., Alvarsson, A., Bj\u00f6rklund, A. & Svenningsson, P. Depressive-like phenotype induced by AAV-mediated overexpression of human \u03b1-synuclein in midbrain dopaminergic neurons. Exp. Neurol. 273, 243\u2013252 (2015).","journal-title":"Exp. Neurol."},{"key":"34884_CR36","doi-asserted-by":"publisher","first-page":"988","DOI":"10.1016\/j.bbrc.2015.07.007","volume":"464","author":"J Lu","year":"2015","unstructured":"Lu, J., Sun, F., Ma, H., Qing, H. & Deng, Y. Comparison between \u03b1-synuclein wild-type and A53T mutation in a progressive Parkinson\u2019s disease model. Biochem. Biophys. Res. Commun. 464, 988\u2013993 (2015).","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"34884_CR37","doi-asserted-by":"publisher","first-page":"9032","DOI":"10.1007\/s12035-024-04131-6","volume":"61","author":"S Hui","year":"2024","unstructured":"Hui, S. et al. Mitophagy upregulation occurs early in the neurodegenerative process mediated by \u03b1-synuclein. Mol. Neurobiol. 61, 9032\u20139042 (2024).","journal-title":"Mol. Neurobiol."},{"key":"34884_CR38","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1038\/s41467-023-37464-2","volume":"14","author":"S Nim","year":"2023","unstructured":"Nim, S. et al. Disrupting the \u03b1-synuclein-ESCRT interaction with a peptide inhibitor mitigates neurodegeneration in preclinical models of Parkinson\u2019s disease. Nat. Commun. 14, 2150 (2023).","journal-title":"Nat. Commun."},{"key":"34884_CR39","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ana.24947","volume":"81","author":"T Musacchio","year":"2017","unstructured":"Musacchio, T. et al. Subthalamic nucleus deep brain stimulation is neuroprotective in the A53T \u03b1-synuclein Parkinson\u2019s disease rat model. Ann. Neurol. 81, 825\u2013836 (2017).","journal-title":"Ann. Neurol."},{"key":"34884_CR40","doi-asserted-by":"crossref","unstructured":"Hofman, K. et al. Low \u03b2 predicts motor output and cell degeneration in the A53T Parkinson\u2019s disease rat model. Brain 148, 4058-4071 (2025).","DOI":"10.1093\/brain\/awaf063"},{"key":"34884_CR41","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1093\/aje\/kwg068","volume":"157","author":"SK Van Den Eeden","year":"2003","unstructured":"Van Den Eeden, S. K. Incidence of Parkinson\u2019s disease: Variation by age, gender, and race\/ethnicity. Am. J. Epidemiol. 157, 1015\u20131022 (2003).","journal-title":"Am. J. Epidemiol."},{"key":"34884_CR42","doi-asserted-by":"publisher","first-page":"1639","DOI":"10.1007\/s00415-011-6392-3","volume":"259","author":"P Martinez-Martin","year":"2012","unstructured":"Martinez-Martin, P. et al. Gender-related differences in the burden of non-motor symptoms in Parkinson\u2019s disease. J. Neurol. 259, 1639\u20131647 (2012).","journal-title":"J. Neurol."},{"key":"34884_CR43","doi-asserted-by":"crossref","unstructured":"Chen, K. S. et al. Small molecule inhibitors of \u03b1-synuclein oligomers identified by targeting early dopamine-mediated motor impairment in C. elegans. Mol. Neurodegener. 16, 77 (2021).","DOI":"10.1186\/s13024-021-00497-6"},{"key":"34884_CR44","unstructured":"Paxinos, G. & Watson, C. The Rat Brain in Stereotaxic Coordinates. (2013)."},{"key":"34884_CR45","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.ibneur.2023.02.001","volume":"14","author":"VE L\u00f3pez-Alonso","year":"2023","unstructured":"L\u00f3pez-Alonso, V. E. et al. The central blockade of the dopamine DR4 receptor decreases sucrose consumption by modifying the microstructure of drinking behavior in male rats. IBRO Neurosci. Rep. 14, 195\u2013201 (2023).","journal-title":"IBRO Neurosci. Rep."},{"key":"34884_CR46","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neulet.2017.08.019","volume":"658","author":"A Blasco-Serra","year":"2017","unstructured":"Blasco-Serra, A., Gonz\u00e1lez-Soler, E. M., Cervera-Ferri, A., Teruel-Mart\u00ed, V. & Valverde-Navarro, A. A. A standardization of the novelty-suppressed feeding test protocol in rats. Neurosci. Lett. 658, 73\u201378 (2017).","journal-title":"Neurosci. Lett."},{"key":"34884_CR47","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/j.neubiorev.2005.03.017","volume":"29","author":"SC Dulawa","year":"2005","unstructured":"Dulawa, S. C. & Hen, R. Recent advances in animal models of chronic antidepressant effects: The novelty-induced hypophagia test. Neurosci. Biobehav. Rev. 29, 771\u2013783 (2005).","journal-title":"Neurosci. Biobehav. Rev."},{"key":"34884_CR48","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1037\/0735-7044.103.1.209","volume":"103","author":"SR Bodnoff","year":"1989","unstructured":"Bodnoff, S. R., Suranyi-Cadotte, B. E., Quirion, R. & Meaney, M. J. Role of the central benzodiazepine receptor system in behavioral habituation to novelty. Behav. Neurosci. 103, 209\u2013212 (1989).","journal-title":"Behav. Neurosci."},{"key":"34884_CR49","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.bbr.2013.05.064","volume":"252","author":"J Francis-Oliveira","year":"2013","unstructured":"Francis-Oliveira, J. et al. Fluoxetine exposure during pregnancy and lactation: Effects on acute stress response and behavior in the novelty-suppressed feeding are age and gender-dependent in rats. Behav. Brain Res. 252, 195\u2013203 (2013).","journal-title":"Behav. Brain Res."},{"key":"34884_CR50","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.bbr.2018.02.023","volume":"345","author":"E Tarland","year":"2018","unstructured":"Tarland, E. & Brosda, J. Male rats treated with subchronic PCP show intact olfaction and enhanced interest for a social odour in the olfactory habituation\/dishabituation test. Behav. Brain Res. 345, 13\u201320 (2018).","journal-title":"Behav. Brain Res."},{"key":"34884_CR51","doi-asserted-by":"crossref","unstructured":"Arbuckle, E. P., Smith, G. D., Gomez, M. C. & Lugo, J. N. Testing for odor discrimination and habituation in mice. J Vis. Exp. 99, 52615 (2015).","DOI":"10.3791\/52615"},{"key":"34884_CR52","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s13024-017-0213-9","volume":"12","author":"Y Wang","year":"2017","unstructured":"Wang, Y., Wu, Z., Bai, Y.-T., Wu, G.-Y. & Chen, G. Gad67 haploinsufficiency reduces amyloid pathology and rescues olfactory memory deficits in a mouse model of Alzheimer\u2019s disease. Mol. Neurodegener. 12, 73 (2017).","journal-title":"Mol. Neurodegener."},{"key":"34884_CR53","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","volume":"13","author":"M Antunes","year":"2012","unstructured":"Antunes, M. & Biala, G. The novel object recognition memory: neurobiology, test procedure, and its modifications. Cogn. Process 13, 93\u2013110 (2012).","journal-title":"Cogn. Process"},{"key":"34884_CR54","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.neuroscience.2011.11.016","volume":"202","author":"OY Chao","year":"2012","unstructured":"Chao, O. Y., Pum, M. E., Li, J.-S. & Huston, J. P. The grid-walking test: assessment of sensorimotor deficits after moderate or severe dopamine depletion by 6-hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle. Neuroscience 202, 318\u2013325 (2012).","journal-title":"Neuroscience"},{"key":"34884_CR55","volume":"25","author":"MH Shihan","year":"2021","unstructured":"Shihan, M. H., Novo, S. G., Le Marchand, S. J., Wang, Y. & Duncan, M. K. A simple method for quantitating confocal fluorescent images. Biochem. Biophys. Rep. 25, 100916 (2021).","journal-title":"Biochem. Biophys. Rep."},{"key":"34884_CR56","doi-asserted-by":"publisher","first-page":"6363","DOI":"10.1038\/s41598-017-06724-9","volume":"7","author":"J-A Phan","year":"2017","unstructured":"Phan, J.-A. et al. Early synaptic dysfunction induced by \u03b1-synuclein in a rat model of Parkinson\u2019s disease. Sci. Rep. 7, 6363 (2017).","journal-title":"Sci. Rep."},{"key":"34884_CR57","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/j.tins.2016.09.003","volume":"39","author":"NP Visanji","year":"2016","unstructured":"Visanji, N. P. et al. \u03b1-Synuclein-based animal models of Parkinson\u2019s disease: Challenges and opportunities in a new era. Trends Neurosci. 39, 750\u2013762 (2016).","journal-title":"Trends Neurosci."},{"key":"34884_CR58","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1006\/exnr.2002.7891","volume":"175","author":"R Deumens","year":"2002","unstructured":"Deumens, R., Blokland, A. & Prickaerts, J. Modeling Parkinson\u2019s disease in rats: An evaluation of 6-OHDA lesions of the nigrostriatal pathway. Exp. Neurol. 175, 303\u2013317 (2002).","journal-title":"Exp. Neurol."},{"key":"34884_CR59","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41596-018-0011-z","volume":"13","author":"M-Y Liu","year":"2018","unstructured":"Liu, M.-Y. et al. Sucrose preference test for measurement of stress-induced anhedonia in mice. Nat Protoc 13, 1686\u20131698 (2018).","journal-title":"Nat Protoc"},{"key":"34884_CR60","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/0306-4522(95)00571-4","volume":"72","author":"CS Lee","year":"1996","unstructured":"Lee, C. S., Sauer, H. & Bj\u00f6rklund, A. Dopaminergic neuronal degeneration and motor impairments following axon terminal lesion by intrastriatal 6-hydroxydopamine in the rat. Neuroscience 72, 641\u2013653 (1996).","journal-title":"Neuroscience"},{"key":"34884_CR61","doi-asserted-by":"crossref","unstructured":"G\u00f3mez-Benito, M. et al. Modeling Parkinson\u2019s disease with the alpha-synuclein protein. Front. Pharmacol. 11, 356 (2020).","DOI":"10.3389\/fphar.2020.00356"},{"key":"34884_CR62","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s004019900168","volume":"100","author":"PM Mattila","year":"2000","unstructured":"Mattila, P. M. et al. Alpha-synuclein-immunoreactive cortical Lewy bodies are associated with cognitive impairment in Parkinson\u2019s disease. Acta. Neuropathol. 100, 285\u2013290 (2000).","journal-title":"Acta. Neuropathol."},{"key":"34884_CR63","doi-asserted-by":"crossref","unstructured":"Hatami, A. & Chesselet, M.-F. Transgenic rodent models to study alpha-synuclein pathogenesis, with a focus on cognitive deficits. Curr. Top. Behav. Neurosci. 22, 303\u2013330 (2015).","DOI":"10.1007\/7854_2014_355"},{"key":"34884_CR64","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.neurol.2012.06.015","volume":"168","author":"A Buot","year":"2012","unstructured":"Buot, A. & Yelnik, J. Functional anatomy of the basal ganglia: Limbic aspects. Rev. Neurol. (Paris)\u00a0168, 569\u2013575 (2012).","journal-title":"Rev. Neurol. (Paris)"},{"key":"34884_CR65","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1177\/1073858420974336","volume":"28","author":"SA Azizi","year":"2022","unstructured":"Azizi, S. A. Monoamines: Dopamine, norepinephrine, and serotonin, beyond modulation, \u201cswitches\u201d that alter the state of target networks. Neuroscientist 28, 121\u2013143 (2022).","journal-title":"Neuroscientist"},{"key":"34884_CR66","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.bbr.2013.10.035","volume":"259","author":"RM Santiago","year":"2014","unstructured":"Santiago, R. M. et al. Induction of depressive-like behavior by intranigral 6-OHDA is directly correlated with deficits in striatal dopamine and hippocampal serotonin. Behav. Brain. Res. 259, 70\u201377 (2014).","journal-title":"Behav. Brain. Res."},{"key":"34884_CR67","doi-asserted-by":"publisher","first-page":"1104","DOI":"10.1016\/j.pnpbp.2010.06.004","volume":"34","author":"RM Santiago","year":"2010","unstructured":"Santiago, R. M. et al. Depressive-like behaviors alterations induced by intranigral MPTP, 6-OHDA, LPS and rotenone models of Parkinson\u2019s disease are predominantly associated with serotonin and dopamine. Prog. Neuropsychopharmacol. Biol. Psychiatry 34, 1104\u20131114 (2010).","journal-title":"Prog. Neuropsychopharmacol. Biol. Psychiatry"},{"key":"34884_CR68","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.neurol.2015.09.012","volume":"172","author":"A Elbaz","year":"2016","unstructured":"Elbaz, A., Carcaillon, L., Kab, S. & Moisan, F. Epidemiology of Parkinson\u2019s disease. Rev. Neurol. (Paris) 172, 14\u201326 (2016).","journal-title":"Rev. Neurol. (Paris)"},{"key":"34884_CR69","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1002\/mdc3.13584","volume":"10","author":"A Zirra","year":"2023","unstructured":"Zirra, A. et al. Gender differences in the prevalence of Parkinson\u2019s disease. Mov. Disord. Clin. Pract. 10, 86\u201393 (2023).","journal-title":"Mov. Disord. Clin. Pract."},{"key":"34884_CR70","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1038\/s41531-020-0109-1","volume":"6","author":"TH Reekes","year":"2020","unstructured":"Reekes, T. H. et al. Sex specific cognitive differences in Parkinson disease. NPJ Parkinsons Dis. 6, 7 (2020).","journal-title":"NPJ Parkinsons Dis."},{"key":"34884_CR71","doi-asserted-by":"publisher","first-page":"1339716","DOI":"10.3389\/fneur.2024.1339716","volume":"15","author":"BR Maas","year":"2024","unstructured":"Maas, B. R. et al. Age and gender differences in non-motor symptoms in people with Parkinson\u2019s disease. Front. Neurol. 15, 1339716 (2024).","journal-title":"Front. Neurol"},{"key":"34884_CR72","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1385\/ENDO:21:1:77","volume":"21","author":"H Sawada","year":"2003","unstructured":"Sawada, H. & Shimohama, S. Estrogens and Parkinson disease: Novel approach for neuroprotection. Endocrine 21, 77\u201380 (2003).","journal-title":"Endocrine"},{"key":"34884_CR73","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1016\/j.pbb.2004.04.022","volume":"78","author":"GE Gillies","year":"2004","unstructured":"Gillies, G. E., Murray, H. E., Dexter, D. & McArthur, S. Sex dimorphisms in the neuroprotective effects of estrogen in an animal model of Parkinson\u2019s disease. Pharmacol. Biochem. Behav. 78, 513\u2013522 (2004).","journal-title":"Pharmacol. Biochem. Behav."},{"key":"34884_CR74","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S0306-4522(02)00578-X","volume":"116","author":"HE Murray","year":"2003","unstructured":"Murray, H. E. et al. Dose- and sex-dependent effects of the neurotoxin 6-hydroxydopamine on the nigrostriatal dopaminergic pathway of adult rats: differential actions of estrogen in males and females. Neuroscience 116, 213\u2013222 (2003).","journal-title":"Neuroscience"},{"key":"34884_CR75","doi-asserted-by":"publisher","DOI":"10.1016\/j.jneuroim.2025.578610","volume":"403","author":"R Bovenzi","year":"2025","unstructured":"Bovenzi, R. et al. Sex-specific immune-biological profiles in Parkinson\u2019s disease. J. Neuroimmunol. 403, 578610 (2025).","journal-title":"J. Neuroimmunol."},{"key":"34884_CR76","doi-asserted-by":"publisher","first-page":"977","DOI":"10.3390\/biom13060977","volume":"13","author":"J Lamontagne-Proulx","year":"2023","unstructured":"Lamontagne-Proulx, J. et al. Sex and age differences in a progressive synucleinopathy mouse model. Biomolecules 13, 977 (2023).","journal-title":"Biomolecules"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34884-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34884-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:03:50Z","timestamp":1770638630000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-34884-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,19]]},"references-count":76,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["34884"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-34884-6","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,19]]},"assertion":[{"value":"15 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 December 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5462"}}